PHILADELPHIA – When effective COVID-19 vaccines are developed, their supply will inevitably be scarce. The World Health Organization (WHO), global leaders, and vaccine producers are already facing the question of how to appropriately allocate them across countries. And while there is vocal commitment to “fair and equitable” distribution, what exactly does “fair and equitable” look like in practice?
Now, nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution — called the Fair Priority Model — which aims to reduce premature deaths and other irreversible health consequences from COVID-19. Published this week in Science, the paper was led by Ezekiel J. Emanuel, MD, PhD, vice provost for Global Initiatives and chair of Medical Ethics and Health Policy in the Perelman School of Medicine at the University of Pennsylvania.
Though little progress has been made to describe a single, global distribution framework for COVID-19 vaccines, two main proposals have emerged: Some experts have argued that health care workers and high-risk populations, such as people over 65, should be immunized first. The WHO, on the other hand, suggests countries receive doses proportional to their populations.
From an ethical perspective, both of these strategies are “seriously flawed,” according to Emanuel and his collaborators.
“The idea of distributing vaccines by population appears to be an equitable strategy,” Emanuel said. “But the fact is that normally, we distribute things based on how severe there is suffering in a given place, and, in this case, we argue that the primary measure of suffering ought to be the number of premature deaths that a vaccine would prevent.”
In their proposal, the authors point to three fundamental values that must be considered when distributing a COVID-19 vaccine among countries: Benefiting people and limiting harm, prioritizing the disadvantaged, and giving equal moral concern for all individuals. The Fair Priority Model addresses these values by focusing on mitigating three types of harms caused by COVID-19: death and permanent organ damage, indirect health consequences, such as health care system strain and stress, as well as economic destruction.
Of all of these dimensions, preventing death — especially premature death — is particularly urgent, the authors argue, which is the focus of Phase 1 of the Fair Priority Model. Premature deaths from COVID-19 are determined in each country by calculating “standard expected years of life lost,” a commonly-used global health metric. In Phase 2, the authors propose two metrics that capture overall economic improvement and the extent to which people would be spared from poverty. And in Phase 3, countries with higher transmission rates are initially prioritized, but all countries should eventually receive sufficient vaccines to halt transmission — which is projected to require that 60 to 70 percent of the population be immune.
The WHO plan, by contrast, begins with 3 percent of each country’s population receiving vaccines, and continues with population-proportional allocation until every country has vaccinated 20 percent of its citizens. Emanuel and his coauthors argue that, while that plan may be politically tenable, it “mistakenly assumes that equality requires treating differently-situated countries identically, rather than equitably responding to their different needs.” In reality, equally populous countries are facing dramatically different levels of death and economic devastation from the pandemic, they say.
The authors also object to a plan that would prioritize countries according to the number of front-line health care workers, the proportion of the population over 65, and the number of people with comorbidities within each country. They say that preferentially immunizing health care workers — who already have access to personal protective equipment (PPE) and other advanced infectious disease prevention methods — likely would not substantially reduce harm in higher-income countries. Similarly, focusing on vaccinating countries with older populations would not necessarily reduce the spread of the virus or minimize death. Moreover, low- and middle-income countries have fewer older residents and health care workers per capita than higher-income countries.
“What you end up doing is giving a lot of vaccine to rich countries, which doesn’t seem like the goal of fair and equitable distribution,” Emanuel said.
The authors conclude that the Fair Priority Model is the best embodiment of the ethical values of limiting harms, benefiting the disadvantaged, and recognizing equal concern for all people.
“It will be up to political leaders, the WHO, and manufacturers to implement this model,” Emanuel said. “Decision-makers are looking for a framework to ensure that everyone throughout the world can be vaccinated, so that we can stop the spread of this virus.”
Other institutions involved in work include the University of Denver, Princeton University, University of Arizona, University of Oxford, University of Melbourne, University of Toronto, University of Groningen, University of Manitoba, Jobs Creation Commission of Ethiopia, Facultad Latinoamerica de Ciencias Sociales (FLACSO) in Argentina, University of Bergen, Norwegian Institute of Public Health, National University of Singapore, Washington University in St. Louis, and Georgetown University.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.9 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.